pharma · Pulmonary Arterial Hypertension · Iron Deficiency Anemia · KROS
Keros Therapeutics
K2B Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker KROS. Primary therapeutic focus areas include Pulmonary Arterial Hypertension, Iron Deficiency Anemia. NovaPharmaN
Cambridge, USA HQ
2021 Founded
10 Employees
Public company Type
KROS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2021
- Employees
- 10
- Programs
- 3
- Drugs
- 2
- Patents
- 12
Dose A KER-012
Phase 2 · mab · Pulmonary Arterial Hypertension
Dose A KER-012 for Pulmonary Arterial Hypertension is a Phase 2 program (mab) at Keros Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code KER-012-A201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Keros Therapeutics
- Phase
- Phase 2
- Modality
- mab
- Indication
- Pulmonary Arterial Hypertension
- Status
- completed
- Trials
- 1